SCHEMBL216145

SCHEMBL216145

CN(C)CCN1CCOc2c[c]ccc21

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.44
NOS1 P29475 2/20 0.44
NOS2 P35228 2/20 0.44
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
PTK2B Q14289 1/20 0.41
ESR2 Q92731 1/20 0.41
HTR1D P28221 2/20 0.36
HTR1B P28222 1/20 0.36
HTR2A P28223 1/20 0.36
HTR1A P08908 1/20 0.34
SLC6A4 P31645 1/20 0.34
KMT2A Q03164 1/20 0.32
KCNH2 Q12809 1/20 0.31
HTR2C P28335 1/20 0.30
AR P10275 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1451559 0.89 NOS3 (0.47) NOS3NOS1NOS2KDM4EALDH1A1
SCHEMBL15450789 0.76 NOS3 (0.53) NOS3NOS1NOS2KDM4EALDH1A1
SCHEMBL54818 0.76 CYP11B1 (0.41) ALDH1A1AR
SCHEMBL215105 0.75 ALDH1A1 (0.63) NOS3NOS1NOS2KDM4EALDH1A1
SCHEMBL218638 0.75 NOS3 (0.54) NOS3NOS1NOS2KDM4EALDH1A1
SCHEMBL499229 0.75 NOS3 (0.54) NOS3NOS1NOS2KDM4EALDH1A1
SCHEMBL1581940 0.75 NOS3 (0.52) NOS3NOS1NOS2KDM4EALDH1A1
SCHEMBL1226210 0.74 KMT2A (0.33) KMT2ATSHR
SCHEMBL10264003 0.74 NOS3 (0.51) NOS3NOS1NOS2KDM4EALDH1A1
SCHEMBL217201 0.74 NOS3 (0.47) NOS3NOS1ALDH1A1HTR2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
EP-2387395-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP disclosed
US-8040491-B2 Exposure method, substrate stage, exposure apparatus, and device manufacturing method NIKON CORPORATION (JP) 2011-10-18 US disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK NOS3 788/4885NOS1 1085/4885NOS2 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.